Wernicke's encephalopathy in a child with high dose thiamine therapy

So Won Park, MD¹, Yoon Young Yi, MD², Jung Woo Han, MD, PhD³, Heung Dong Kim, MD, PhD¹, Joon Soo Lee, MD, PhD¹, Hoon-Chul Kang, MD, PhD¹

¹Division of Pediatric Neurology, Department of Pediatrics, Pediatric Epilepsy Clinic, Severance Children's Hospital, Epilepsy Research Institute, Yonsei University College of Medicine, Seoul, ²Department of Pediatrics, Hallym University Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, ³Division of Pediatric Hemato-Oncology, Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea

Wernicke's encephalopathy is an acute neurological disorder characterized by mental confusion, oculomotor dysfunction, and ataxia. It has been reported in individuals with alcohol dependence, hyperemesis gravidarum, and prolonged parenteral nutrition without vitamin supplementation. Here we present the case of a 13-year-old male patient with neuroblastoma and a history of poor oral intake and nausea for 3 months. After admission, he showed gait disturbances, nystagmus, and excessive dizziness; his mental state, however, indicated he was alert, which did not fit the classical triad of Wernicke's encephalopathy. A diagnosis of Wernicke's encephalopathy was made only after brain magnetic resonance imaging and serum thiamine level analyses were performed. The patient's symptoms remained after 5 days of treatment with 100-mg thiamine once daily; thus, we increased the dosage to 500 mg three times a day, 1,500 mg per day. His symptoms then improved after 20 days of replacement therapy. This case report describes a pediatric patient who was promptly diagnosed with Wernicke's encephalopathy, despite only 2 suspicious symptoms, and who completely recovered after high doses of thiamine were given intravenously.

Key words: Wernicke encephalopathy, Thiamine deficiency, Parenteral nutrition

Introduction

Wernicke's encephalopathy, first described in 1881 by Carl Wernicke, is an acute neuropsychiatric syndrome that requires emergency treatment to prevent death and neurologic morbidity caused by thiamine (vitamin B₁) deficiency.¹⁻³ The classical triad of Wernicke's encephalopathy includes encephalopathy, oculomotor dysfunction and gait ataxia.⁴ It is generally associated with alcoholism, anorexia nervosa and hyperemesis gravidarum which in turn induces thiamine deficiency.⁵ In addition, it is also known to be related to prolonged parenteral nutrition without vitamin supplementation in systemic malignancy.⁶⁻⁷

Here we report a case of a 13-year-old boy who was diagnosed with Wernicke's encephalopathy derived from prolonged malnutrition during treatment for a neuroblastoma. He was treated with thiamine of 100 mg daily, and then of higher dosage (i.e., 500 mg three times a day) after 5 days. He was completely recovered after intravenous injection of high-dose thiamine.
Case report

A 13-year-old boy was diagnosed with neuroblastoma stage IV two years previously with no evidence of brain metastasis on initial cerebrospinal fluid study, and he received treatment 6 times with chemotherapy, as well as auto peripheral blood stem cell transplantation (auto PBSCT), therapeutic metaiodobenzylguanidine for residual tumor, and unrelated PBSCT for tumor relapse. When he was discharged from the hospital after successful unrelated PBSCT, he experienced increased nausea and vomiting, and poor oral intake. He was subsequently admitted to receive intravenous amino acid resuscitation (Trophamine) and total parenteral nutrition (TPN). When he was admitted, jitteriness on bilateral upper extremities was observed for a brief time while he was receiving intravenous amino acid resuscitation and TPN therapy. Under the impression of Wernicke's encephalopathy, intravenous thiamine replacement was done. Although his thiamine level came out to be normal (6.9 μg/dL; reference range: 2–7.2 μg/dL), we kept thiamine replacement therapy for one week since his oral intake was very poor. Then we changed intravenous thiamine replacement into oral replacement for one more month to prevent Wernicke's encephalopathy. Brain magnetic resonance imaging (MRI) was not performed since his thiamine level was within normal range then. Since he had no apparent neurological symptoms and his oral intake improved, we discontinued thiamine prophylaxis at discharge. The patient visited the outpatient clinic for reappearing nausea, vomiting and poor oral intake, and received TPN while trying to develop his oral intake. On hospital day 7, he started to complain about dizziness, ataxic gait, and bilateral jerky type multidirectional nystagmus, but his mental status was alert and he did not show sensory changes in his extremities. On the evaluation of dizziness, neurological evaluation and consultation to Otolaryngology Department was done. His dizziness was not associated with spinning sensation, and it was nontrue vertigo type. He had no ear fullness or tinnitus, and his ear drums and hearing function were all intact. On neurological examination, his cranial nerve function test or deep tendon reflex test showed no remarkable findings, and rapid alternating test and finger-to-nose test also showed normal findings. On standing, he was slightly swaying to right side, but he had no unilateral motor power impairment. Consultation to the Ophthalmology Department was done, and there was no papilledema or diplopia on physical examination. His brain computed tomography was unremarkable. However, brain MRI showed hyperintense lesions in the bilateral medial thalami and periaqueductal gray matter was visible in T2-weighted and fluid-attenuated inversion recovery images, characteristic of Wernicke's encephalopathy (Fig. 1A). An electroencephalogram showed somewhat slow and disorganized background rhythms, which were compatible with mild degree of diffuse brain dysfunction.

Under the impression of Wernicke's encephalopathy, we started intravenous replacement of thiamine 100 mg daily. On treatment day 5, his symptoms improved slightly, but nystagmus and dizziness remained. We then increased the amount of thiamine replacement to 200 mg daily. On treatment day 9, he showed remarkable improvement in his gait and had no dizziness, ataxia, or nystagmus. On treatment day 12, he showed further improvement and was discharged. Since he had no apparent neurological symptoms and his oral intake improved, we discontinued thiamine prophylaxis at discharge. The patient visited the outpatient clinic for reappearing nausea, vomiting and poor oral intake, and received TPN on a regular basis. None of his symptoms did not improve and his general weakness increased. He was readmitted 3 months later.

One review of system, the patient had poor oral intake with nausea and vomiting, and he had lost 13 kg over 2 months. His initial vital signs were stable and his mental status was alert. Our initial physical examination did not reveal any abnormal neurological signs. Laboratory tests showed pancytopenia and elevated liver enzymes (The white blood cell count, hemoglobin level, and platelet count were 2,960/μL, 8.4 g/dL, and 139,000/μL respectively. His level for aspartate aminotransferase and alanine aminotransferase was 62 IU/L and 69 IU/L correspondingly).

There were no specific findings from a brain MRI that was carried out on the day of admission in order to exclude brain metastasis. The patient received TPN replacement therapy while trying to develop his oral intake. On hospital day 7, he started to complain about dizziness, ataxic gait, and bilateral jerky type multidirectional nystagmus, but his mental status was alert and he did not show sensory changes in his extremities. On the evaluation of dizziness, neurological evaluation and consultation to Otolaryngology Department was done. His dizziness was not associated with spinning sensation, and it was nontrue vertigo type. He had no ear fullness or tinnitus, and his ear drums and hearing function were all intact. On neurological examination, his cranial nerve function test or deep tendon reflex test showed no remarkable findings, and rapid alternating test and finger-to-nose test also showed normal findings. On standing, he was slightly swaying to right side, but he had no unilateral motor power impairment. Consultation to the Ophthalmology Department was done, and there was no papilledema or diplopia on physical examination. His brain computed tomography was unremarkable. However, brain MRI showed hyperintense lesions in the bilateral medial thalami and periaqueductal gray matter was visible in T2-weighted and fluid-attenuated inversion recovery images, characteristic of Wernicke’s encephalopathy (Fig. 1A). An electroencephalogram showed somewhat slow and disorganized background rhythms, which were compatible with mild degree of diffuse brain dysfunction.

Under the impression of Wernicke’s encephalopathy, we started intravenous replacement of thiamine 100 mg daily. On treatment day 5, his symptoms improved slightly, but nystagmus and dizziness remained. We then increased the amount of thiamine replacement to 200 mg daily. On treatment day 9, he showed remarkable improvement in his gait and had no dizziness, ataxia, or nystagmus. On treatment day 12, he showed further improvement and was discharged. Since he had no apparent neurological symptoms and his oral intake improved, we discontinued thiamine prophylaxis at discharge.

Fig. 1. (A) Bilateral hyperintense lesions are noted in the medial thalami on T2-weighted images (arrows). (B) Improved lesions, but remnant lesions are seen in brain magnetic resonance images after 9 days of thiamine replacement. (C) After 2 months of thiamine replacement, brain magnetic resonance imaging revealed normal findings.
replacement to 500 mg three times a day. Brain MRI at 9 days of thiamine replacement showed a slight improvement but the lesions remained (Fig. 1B). The patient's dizziness and nystagmus improved and disappeared upon treatment days 10 and 14, respectively. He was discharged with an oral thiamine supplement on treatment day 18. The patient's thiamine level was 1.5 μg/dL when he was first diagnosed with Wernicke's encephalopathy, but his thiamine level was over 9 μg/dL before he was discharged from the hospital.

His oral intake did not improve significantly after he was discharged, and he was readmitted to our hospital two more times for intravenous thiamine replacement although he did not complain of any symptoms related to Wernicke's encephalopathy. On that time, follow-up of brain MRI was performed, and the image was improving compared to the MRI when he was first diagnosed with Wernicke's encephalopathy. His brain MRI after two months of thiamine replacement was normal (Fig. 1C).

Discussion

Wernicke's encephalopathy is caused by thiamine deficiency primarily in alcoholics, and it can also occur in impaired nutritional states including gastrointestinal disorders, hyperemesis gravidarum and malignant diseases. Thiamine pyrophosphate is a cofactor of the pyruvate dehydrogenase complex, alpha-ketoglutarate dehydrogenase, and transketolase. These enzymes play a key role in the regulation of glucose and energy metabolism in the brain. Therefore, when there is a shortage of thiamine, cells fail to meet their metabolic demands, and eventually it leads to metabolic acidosis, cell death, and external imbalance. Brain tissue from patients with Wernicke's encephalopathy shows selective damage to subcortical areas of the brain that include the thalamus and mammillary bodies. Oxidative stress, glutamate-mediated excitotoxicity and inflammation are major contributors to regional neurodegeneration in Wernicke's encephalopathy.

A previous study detected the clinical triad of oculomotor symptoms, ataxia, and mental confusion in only 16% of Wernicke's encephalopathy patients. Another study reported that the classic clinical triad was present in only 0.4% cases at onset. In our case, the patient showed dizziness, nystagmus and ataxia, but his mental status was alert until recovery. The relatively nonspecific nature of the clinical presentation may have delayed the diagnosis in many cases. Early signs and symptoms include loss of appetite, nausea, weakness, giddiness, diplopia, memory loss and difficulty in concentration. It is not until the later stage when the patient shows signs and symptoms of the classic triad, hallucination, and coma, yet early intervention with thiamine replacement is essential to reverse the symptoms of Wernicke's encephalopathy. Brain MRI is the most sensitive technique and is required for all patients in whom Wernicke's encephalopathy is suspected. Medial thalami, mammillary bodies, tegmentum, periaqueductal region, and tectal plate are typical sites of abnormal MRI signals. The dorsal medulla, red nuclei, cranial nerve nuclei, cerebellum, corpus callosum, frontal and parietal cerebral cortex are less common sites of involvement although they are more frequently affected in nonalcoholic cases. In our case, brain MRI revealed the involvement of bilateral medial thalami and periaqueductal gray matter.

Empiric thiamine replacement should be initiated as soon as Wernicke's encephalopathy is suspected. Delayed treatment may increase the likelihood of morbidity or mortality. Patients require IV administration of at least 100 mg of thiamine daily for several days in Wernicke's encephalopathy. However, in order to prevent permanent damage (i.e., Korsakoff syndrome), the British National Formulary and the Royal College of Physicians, London (Royal College of Physicians 2001) recommend the immediate treatment guideline for Wernicke's encephalopathy in alcoholics. Thiamine 500 mg IV three times daily for 2 to 3 days and 250 mg IV daily for the next 3 to 5 days are recommended as immediate treatment. However, there is no fixed guideline for pediatric patient who was diagnosed with Wernicke's encephalopathy. Dosage of 50–100 mg daily or 1.8-mg thiamine per 1,000 kcal has been suggested in pediatric patients, and 100 mg of daily thiamine replacement is routinely recommended in pediatric patients. Furthermore, although high dose of thiamine replacement has not been documented in pediatric patients, high dose of thiamine therapy has been reported in nonalcoholic adult patient. In our case, symptoms remained after use of 100 mg of thiamine when our patient was diagnosed with Wernicke's encephalopathy, so we increased the dose to 500 mg three times daily although Wernicke's encephalopathy was not alcohol induced. The patient was symptom-free after 1 week of high-dose thiamine replacement therapy. We prescribed him with oral thiamine on his discharge for supplementation. Furthermore, we have readmitted our patient for thiamine treatment therapy two more times after his discharge. Although he did not manifest a classical triad other than poor oral intake and general weakness, immediate replacement of thiamine helped him to recover his general condition.

In this report, we presented a case report of Wernicke's encephalopathy associated with prolonged malnutrition due to malignancy in a child. Since early diagnosis and optimal dosing is needed for complete recovery, it is important to suspect Wernicke's encephalopathy and replace thiamine actively although the initial symptoms may not be typical. Moreover, a high dose of thiamine (500 mg three times daily) should also be considered immediately in the pediatric patient with incomplete recovery from Wernicke's encephalopathy.
Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This work was supported by a National Research Foundation grant funded by the Korean Government (MEST, 2010-0020353).

References

1. Wernicke C. Lehrbuch der Gehirnkrankheiten fur Aerzte und Studirende. Vol. 2. Theodor Fischer. Berlin: Kassel, 1881:229-42.
2. Hazell AS, Butterworth RF. Update of cell damage mechanisms in thiamine deficiency: focus on oxidative stress, excitotoxicity and inflammation. Alcohol Alcohol 2009;44:141-7.
3. Campbell AC, Russel WR. Wernicke’s encephalopathy: the clinical features and their probable relationship to vitamin B deficiency. Q J Med 1941;10:41-64.
4. Harper CG, Giles M, Finlay-Jones R. Clinical signs in the Wernicke-Korsakoff complex: a retrospective analysis of 131 cases diagnosed at necropsy. J Neurol Neurosurg Psychiatry 1986;49:341-5.
5. Sechi G, Serra A. Wernicke’s encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol 2007;6:442-55.
6. Thomson AD, Guerrini I, Bell D, Drummond C, Duka T, Field M, et al. Alcohol-related brain damage: report from a Medical Council on Alcohol Symposium, June 2010. Alcohol Alcohol 2012;47:84-91.
7. Harper CG, Butterworth RF. Nutritional and metabolic disorders. In: Graham DL, Lantos PL, editors. Greenfield’s neuropathology. London: Arnold, 1997:601-55.
8. Brew BJ. Diagnosis of Wernicke’s encephalopathy. Aust N Z J Med 1986;16:676-8.
9. Galvin R, Brathen G, Ivashynka A, Hillbom M, Tanasescu R, Leone MA, et al. EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol 2010;17:1408-18.
10. Vasconcelos MM, Silva KP, Vidal G, Silva AF, Domingues RC, Berditchevsky CR. Early diagnosis of pediatric Wernicke’s encephalopathy. Pediatr Neurol 1999;20:289-94.
11. Manzanares W, Hardy G. Thiamine supplementation in the critically ill. Curr Opin Clin Nutr Metab Care 2011;14:610-7.
12. Cerase A, Rubenni E, Rufa A, Vallone I, Galluzzi P, Coratti G, et al. CT and MRI of Wernicke’s encephalopathy. Radiol Med 2011;116:319-33.
13. Bae SN, Kim BJ, Park SS, Nam SO, Lim YT, Kim HJ. A case of Wernicke’s encephalopathy which occurred during chemotherapy in a child with acute myeloblastic leukemia. J Korean Pediatr Soc 2001;44:1320-5.
14. Thomson AD, Cook CC, Touquet R, Henry JA; Royal College of Physicians, London. The Royal College of Physicians report on alcohol: guidelines for managing Wernicke’s encephalopathy in the accident and Emergency Department. Alcohol Alcohol 2002;37:513-21.
15. Caso F, Fiorino A, Falautano M, Leocani L, Martinelli V, Minicucci F, et al. Treatment of Wernicke’s encephalopathy with high dose of thiamine in a patient with pyloric sub-stenosis: description of a case. Neurol Sci 2010;31:859-61.